Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Nutr Biochem ; 116: 109310, 2023 06.
Article in English | MEDLINE | ID: mdl-36871839

ABSTRACT

Nicotinamide riboside (NR) is considered a super-supplement that prevents obesity and diabetes. While NR has been investigated for various effects depending on nutritional conditions, metabolic research on women and pregnant women has rarely been discussed. In this study, we focused on the glycemic control of NR in females and found the protective role of NR in pregnant animals under hypoglycemic conditions. Metabolic-tolerance tests were performed in vivo under progesterone (P4) exposure after ovariectomy (OVX). NR enhanced resistance to energy deprivation and showed a slight increase in gluconeogenesis in naïve control mice. However, NR reduced hyperglycemia and significantly induced gluconeogenesis in OVX mice. While NR reduced hyperglycemia in the P4-treated OVX mice, it reduced insulin response and substantially increased gluconeogenesis. Similar to animal experiments, NR increased gluconeogenesis and mitochondrial respiration in Hep3B cells. The gluconeogenic function of NR is mediated by tricarboxylic acid cycle (TCA) cycle enrichment, as residual pyruvate could induce gluconeogenesis. NR recovered fetal growth by increasing blood glucose levels when hypoglycemia was induced by diet-restriction during pregnancy. Our study revealed the glucose-metabolic function of NR in hypoglycemic pregnant animals, suggesting NR as a dietary supplement to improve fetal growth. Because diabetic women suffer from hypoglycemia due to insulin therapy, NR has therapeutic potential for use as a glycemic control pill.


Subject(s)
Hyperglycemia , Hypoglycemia , Female , Humans , Mice , Pregnancy , Animals , Niacinamide/pharmacology , Hypoglycemia/prevention & control , Insulin , Dietary Supplements , Hypoglycemic Agents , Fetal Development , Hyperglycemia/prevention & control
2.
Biochim Biophys Acta Mol Basis Dis ; 1869(5): 166668, 2023 06.
Article in English | MEDLINE | ID: mdl-36822448

ABSTRACT

BACKGROUNDS AND AIMS: Type 2 diabetes mellitus (T2D) is a chronic disease characterized by insulin resistance and hyperglycemia. To investigate T2D, genetic and chemical induced hyper-obese rodent models have been experimentally developed. However, establishment of moderate-obese diabetes model will confer diverse opportunities for translational studies. In this study, we found the chemical, GLUTFOURINH® (GFI), induces post-translational degradation of glucose transporter 4 (GLUT4). We aimed to establish novel diabetic model by using GFI. METHODS AND RESULTS: Low plasma membrane GLUT4 (pmGLUT4) levels by GFI resulted in reduction of intracellular glucose uptake and TG, and increase of intracellular FFA in A204 cells. Likewise, GFI treatment decreased intracellular TG and increased intracellular FFA levels in Hep3B and 3T3-L1 cells. Mice were administered with GFI (16 mg/kg) for short-term (3-day) and long-term (28- and 31-day) to compared with vehicle injection, HFD model, and T2D model, respectively. Short-term and long-term GFI treatments induced hyperglycemia and hyperinsulinemia with low pmGLUT4 levels. Compared to HFD model, long-term GFI with HFD reduced adipose weight and intracellular TG accumulation, but increased plasma FFA. GFI treatment resulted in insulin resistance by showing low QUICKI and high HOMA-IR values, and low insulin response during insulin tolerance test. Additionally, low pmGLUT4 by GFI heightened hyperglycemia, hyperinsulinemia, and insulin resistance compared to T2D model. CONCLUSIONS: In summary, we report GLUT4 degradation by novel chemical (GFI) induces moderate-obese diabetes representing hyperglycemia, insulin resistance and low intracellular lipid accumulation. The GLUT4 degradation by GFI has translational value for studying diseases related to moderate-obese diabetes.


Subject(s)
Diabetes Mellitus, Type 2 , Hyperglycemia , Hyperinsulinism , Insulin Resistance , Humans , Mice , Animals , Insulin Resistance/physiology , Diabetes Mellitus, Type 2/metabolism , Insulin , Hyperglycemia/metabolism , Obesity , Lipids
3.
Int J Mol Sci ; 22(22)2021 Nov 22.
Article in English | MEDLINE | ID: mdl-34830439

ABSTRACT

Hepatocellular carcinoma (HCC) is a male-oriented malignancy; its progression is affected by sex hormones. 17α-ethinylestradiol (EE2) is a synthetic estrogen widely used as an oral contraceptive; however, it is unknown whether EE2 regulates sex hormone action in HCC. We investigated whether EE2 influences HCC risk in male androgenic environments, using mice expressing human sex hormone-binding globulin (SHBG). Two-week-old male mice were injected with diethyl-nitrosamine (DEN, 25 mg/kg) and fed an EE2 diet for 10 weeks from 30 weeks of age. Development and characteristics of liver cancer were evaluated in 40-week-old mice via molecular and histological analyses. Although EE2 did not increase HCC progression in wild-type mice, SHBG mice exhibited remarkably higher HCC risk when fed EE2. The livers of EE2-treated SHBG mice exhibited substantially increased pro-inflammatory necrosis with high plasma levels of ALT and HMGB1, and intrahepatic injury and fibers. Additionally, increased androgen response and androgen-mediated proliferation in the livers of EE2-treated SHBG mice and EE2-exposed hepatocytes under SHBG conditions were observed. As a competitor of SHBG-androgen binding, EE2 could bind with SHBG and increase the bioavailability of androgen. Our results revealed that EE2 is a novel risk factor in androgen-dominant men, predisposing them to HCC risk.


Subject(s)
Androgens/metabolism , Carcinoma, Hepatocellular/genetics , Liver Neoplasms/genetics , Sex Hormone-Binding Globulin/genetics , Androgens/genetics , Animals , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/pathology , Diethylnitrosamine/pharmacology , Disease Models, Animal , Disease Progression , Ethinyl Estradiol/pharmacology , Humans , Liver Neoplasms/etiology , Liver Neoplasms/pathology , Male , Mice , Sex Characteristics
4.
Int Forum Allergy Rhinol ; 8(9): 993-1000, 2018 09.
Article in English | MEDLINE | ID: mdl-29979839

ABSTRACT

BACKGROUND: Exposure to urban particulate matter (UPM) has been linked to aggravation of various health problems. Although the effects of UPM on the lower respiratory tract have been extensively studied, more research is required on the impact of UPM on the upper respiratory tract and the underlying mechanisms. Thus, we investigated the cytotoxic effects of UPM on cultured human nasal fibroblasts, the underlying signaling pathways involved, and changes in cytokine levels. METHODS: Human turbinate tissue specimens were collected during partial turbinectomies performed on 6 patients, and then cultured. The effect of UPM on nasal fibroblast viability was explored. Real-time reverse transcription-polymerase chain reaction was used to measure the mRNA levels of genes encoding cytokines and chemokines (interleukin [IL]-4, IL-6, IL-8, and tumor necrosis factor-α) before and after 24 hours of UPM treatment. Enzyme-linked immunosorbent assays were employed to measure IL-6 and IL-8 levels. The status of the p38 and nuclear factor (NF)-κB signaling pathways was analyzed by Western blotting. RESULTS: UPM reduced cell viability in a dose-dependent manner and increased IL-6 and IL-8 expression at both the mRNA and protein levels. UPM induced the phosphorylation of p38 and NF-κB p65; inhibitors of the actions of these proteins repressed phosphorylation and the expression of IL-6 and IL-8. CONCLUSION: UPM induced IL-6 and IL-8 expression by fibroblasts via p38 and NF-κB classical signaling, suggesting that UPM can induce or aggravate allergic and/or chronic rhinitis.


Subject(s)
Air Pollutants/toxicity , Fibroblasts/drug effects , Particulate Matter/toxicity , Adult , Cell Survival/drug effects , Cells, Cultured , Cytokines/genetics , Cytokines/metabolism , Dose-Response Relationship, Drug , Female , Fibroblasts/immunology , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Male , Middle Aged , Phosphorylation/drug effects , RNA, Messenger/metabolism , Signal Transduction/drug effects , Turbinates/pathology
5.
J Int Adv Otol ; 11(3): 264-6, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26915162

ABSTRACT

Myxoma is a benign connective tissue tumor that is most commonly found in the heart. Because myxoma of the external ear is extremely rare, its diagnosis may be easily delayed or it may be misdiagnosed as another disease. Moreover, because it can be a part of Carney complex (autosomal dominant syndrome), its correct diagnosis is very important. We experienced a 10-year-old girl who had a mass on the posterior surface of the tragus at the entrance of the left ear canal. Fine-needle aspiration revealed mucoid content of the cystic mass, but its cytology did not confirm the diagnosis. The whole mass was surgically removed, and the diagnosis was confirmed as myxoma with a stellate spindle cell proliferation in the hypocellular matrix. Thorough examination failed to determine any presentation of Carney complex, and her final diagnosis was isolated myxoma of the external auditory canal. This is the first reported study regarding myxoma of the external auditory canal in the Korean literature.


Subject(s)
Ear Canal/pathology , Ear Neoplasms/pathology , Myxoma/pathology , Child , Ear Canal/surgery , Ear Neoplasms/surgery , Female , Humans , Myxoma/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...